COST-SYRA3

Innovative Methods in Radiotherapy and Radiosurgery using Synchrotron Radiation (SYRA3) is a COST Action in the Biomedicine and Molecular Biosciences domain funded within the FP7 program. Its aim is to setup and coordinate a multidisciplinary network to develop synchrotron radiotherapy and radiosurgery techniques to treat brain tumours and other diseases of the central nervous system. SYRA3 is funded for the period 2013-2016. It is presently composed by more than 40 laboratories of 14 European and 3 Non-European countries. The ESRF is the Grant Holder of the Action. The Management Committee, composed by representatives of all Countries and chaired by Alberto Bravin, manages the annual activities and the use of funds.